Publications by authors named "V CIOBANU"
The escalating global problem of antibiotic contamination in wastewater demands innovative and sustainable remediation technologies. This paper presents a highly efficient photocatalytic material for water purification: a three-dimensional ultra-porous structure of interconnected GaN hollow microtetrapods (aero-GaN), its performance being further enhanced by noble metal nanodot functionalization. This novel aero-nanomaterial achieves more than 90 % of tetracycline degradation within 120 min under UV and solar irradiation, demonstrating its effectiveness in both static and dynamic flow conditions, with the potential for reuse and recyclability.
View Article and Find Full Text PDFOne of the biggest issues of wide bandgap semiconductor use in photocatalytic wastewater treatment is the reusability of the material and avoiding the contamination of water with the material itself. In this paper, we report on a novel TiO aeromaterial (aero-TiO) consisting of hollow microtetrapods with ZnTiO inclusions. Atomic layer deposition has been used to obtain particles of unique shape allowing them to interlock thereby protecting the photocatalyst from erosion and damage when incorporated in active filters.
View Article and Find Full Text PDFRecent studies underscore the role of gut and oral microbiota in influencing neuroinflammation through the microbiota-gut-brain axis, including in Alzheimer's disease (AD). This review aims to provide a comprehensive synthesis of recent findings on the involvement of gut and oral microbiota in the neuroinflammatory processes associated with AD, emphasizing novel insights and therapeutic implications. This review reveals that dysbiosis in AD patients' gut and oral microbiota is linked to heightened peripheral and central inflammatory responses.
View Article and Find Full Text PDFArticle Synopsis
- Rheumatoid arthritis (RA) patients experience unique challenges when infected with SARS-CoV-2 due to their immunocompromised status and treatments, which complicates their health outcomes compared to the general population.
- The systematic review, adhering to PRISMA guidelines, analyzed literature from 2021-2023 and highlighted issues such as delays in treatment due to COVID-19 fears and increased risk of severe outcomes tied to cardiovascular and metabolic conditions.
- Additionally, the review found that while COVID-19 vaccines are generally safe for RA patients, certain treatments like Methotrexate and Rituximab may weaken their vaccine response, emphasizing the need for tailored medical management during the pandemic.
Background: Rheumatoid arthritis (RA) patients are at heightened risk of Coronavirus Disease-19 (COVID-19) complications due to immune dysregulation, chronic inflammation, and treatment with immunosuppressive therapies. This study aims to characterize the clinical and laboratory parameters of RA patients diagnosed with COVID-19, identify predictive risk factors for severe forms of this infection for RA patients, and determine if any RA immunosuppressive therapy is associated with worse COVID-19 outcomes.
Methods: A retrospective observational case-control study included 86 cases (43 diagnosed with RA and 43 cases without any inflammatory or autoimmune disease) that suffered from SARS-CoV-2 in two Romanian hospitals between March 2020 and February 2024.